FDA moves to fast-track review of psilocybin and methylone for mental health
April 26, 2026
Anxiety Brain Health Depression Mental Health Opioid Policy Science StigmaThe US Food and Drug Administration issued national priority vouchers to three companies studying psychedelic-based medicines.